No Data
No Data
Why Is Larry Robbins Bullish on Myriad Genetics, Inc. (MYGN) Now?
MYGN Stock Gains Following the Launch of Know More Sooner
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
Leerink Partners Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $18
Leerink Partners Sticks to Their Hold Rating for Myriad Genetics (MYGN)
Myriad Genetics Study Shows Increased Completion Rates for Hereditary Cancer Testing Through Online Screening and Education Tools
905745367 OP : It will bounce back